New composite outcomes data show patients treated with Lilly's Omvoh (mirikizumab-mrkz) achieved comprehensive corticosteroid-free disease control in ulcerative colitis and corticosteroid-free deep remission in Crohn's disease at one year

Data ReadoutpositiveOmvohPositive

AI Analysis

Summary

Lilly's Omvoh demonstrated positive Phase 3 data in LUCENT-2, with 27.7% of ulcerative colitis patients achieving comprehensive corticosteroid-free disease control including symptomatic, endoscopic, and histologic remission at one year.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

LUCENT-2 study showed 27.7% of Omvoh-treated ulcerative colitis patients achieved comprehensive disease control (symptomatic, endoscopic, and histologic remission with biomarker normalization and no corticosteroid use) at one year

Importance:7/10

Sentiment:

0.70

ulcerative colitisCrohn's diseaseimmunologyclinical dataremission

Related Companies

$LLY

Read the original article

Published by PR Newswire Biotech on October 15, 2026 12:00 PM

Read Original